InsidersTradesSigma
Follow the 康泰生物 stock price and the full management transaction log of the company, a publicly traded company based in China. Shares are listed on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 康泰生物 has published 4 reports. Market capitalisation: €13.8bn. The latest transaction was disclosed on 31 January 2023 (Purchase). Among the most active insiders: 陶瑾. Every trade is accessible without an account.
4
Insider Decl.
n/a
Thresholds
€655,787
3 ops.
Buy Volume
€3m
1 ops.
Sell Volume
11Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,631 of 29,062 companies
40.3
score / 100
Value33
Quality48
FCF yld2.2%
Earn yld0.5%
EV/EBITDA27.9x
ROE0.8%
Gross mgn75%
Net mgn2.6%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 January 2023
About 康泰生物
康泰生物 is a company in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the development and production of biological and pharmaceutical products.